Lexicon Pharmaceuticals | LXRX - Sales Revenues


Lexicon Pharmaceuticals reported $5.49M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Illumina USD 1.09B 70M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
J&J USD 24.1B 500M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 90.2M 21.76M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Novartis USD 13.11B 226M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024